Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amphotericin B for Breakthrough Invasive Fungal Disease in Hematological Patients
NCT07559032Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of amphotericin b in invasive fungal disease (IFD), sponsored by Peking University People's Hospital. Primary endpoint: Overall Response Rate at 6 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
amphotericin b
03
Conditions
invasive fungal disease (IFD)
Beyond the preview
Go deeper on NCT07559032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07559032.